Valitor, a biotechnology company dedicated to engineering more effective medicines, is proud to announce that two of its abstracts have been accepted for poster presentation at the 2023 ARVO Annual Meeting in New Orleans.
At the conference, attendees will be able to learn about the preclinical data on two of Valitor’s drug candidates: VLTR-557, a long-acting anti-VEGF biologic designed to treat wet age-related macular degeneration, and a single-domain anti-TNFα antibody developed specifically to treat non-infectious uveitis. We look forward to sharing these important findings with the research community.
About the MVP Technology
Valitor’s Multivalent Polymer (MVP) technology platform, born at U.C. Berkeley, allows for unprecedented control over drug design. By coupling proprietary multi-valent biopolymers with bioactive molecules, Valitor is able to assemble novel macromolecular entities that overcome a range of drug design challenges.
These compounds have been proven to show >1,000-fold increases in potency, up to 10-fold increases in tissue retention, and excellent preclinical safety. With this revolutionary approach, Valitor is revolutionizing the way we think about and design drugs.
Valitor is revolutionizing the way we treat diseases by utilizing its multi-valent biopolymer technology to maximize the benefits for patients. By engineering disruptive medicines that target disease mechanisms, the company is driving remarkable clinical impact and significantly improving patient outcomes in ophthalmology and vision-threatening diseases.
Valitor has been recognized and awarded numerous grants from prestigious organizations such as the NCI, NIH, NEI, and NIAMS. Located at the groundbreaking Bakar BioEnginuity Hub at U.C. Berkeley, Valitor is leading the charge towards a brighter and healthier future.